Protocol Ledger

NCT07465718 · Phase III · RECRUITING

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Interventional Phase III clinical trial protocol NCT07465718 sponsored by Orphalan in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-03 Enrollment: 38 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07465718
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07465718
Protocol FieldVerified Registry Value
NCT IdentifierNCT07465718
Consolidated Lead SponsorOrphalan
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment38 participants (ESTIMATED)
Registered Start Date2026-09-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI